$512 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 112 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EIGR | EIGER BIOPHARMACEUTICALS INC | $4,412,000 | -1.7% | 385,301 | 0.0% | 0.86% | -24.0% | |
| TEVA PHARMACEUTICAL FIN LLCdbcv 0.250% 2/0 | $3,800,000 | -10.5% | 6,585 | 0.0% | 0.74% | -30.9% | ||
| AVXS | AVEXIS INC | $3,421,000 | +59.3% | 45,000 | 0.0% | 0.67% | +23.0% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $2,695,000 | +25.0% | 140,000 | 0.0% | 0.53% | -3.5% | |
| XLRN | ACCELERON PHARMA INC | $2,647,000 | +3.7% | 100,000 | 0.0% | 0.52% | -20.0% | |
| CLSD | CLEARSIDE BIOMEDICAL INC | $2,382,000 | -11.2% | 300,000 | 0.0% | 0.47% | -31.4% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $2,282,000 | +91.4% | 166,310 | 0.0% | 0.45% | +47.7% | |
| SMMT | SUMMIT THERAPEUTICS PLCspons ads | $1,967,000 | +55.9% | 147,450 | 0.0% | 0.38% | +20.7% | |
| MGNX | MACROGENICS INC | $1,510,000 | -9.0% | 81,200 | 0.0% | 0.30% | -29.8% | |
| FPRX | FIVE PRIME THERAPEUTICS INC | $1,446,000 | -27.8% | 40,000 | 0.0% | 0.28% | -44.2% | |
| EDGE | EDGE THERAPEUTICS INC | $1,367,000 | -27.1% | 150,000 | 0.0% | 0.27% | -43.8% | |
| XENE | XENON PHARMACEUTICALS INC | $1,312,000 | -48.1% | 328,029 | 0.0% | 0.26% | -59.9% | |
| RARX | RA PHARMACEUTICALS INC | $1,277,000 | +40.2% | 60,000 | 0.0% | 0.25% | +8.2% | |
| VTGN | VISTAGEN THERAPEUTICS INC | $1,066,000 | -47.5% | 544,100 | 0.0% | 0.21% | -59.5% | |
| PTN | PALATIN TECHNOLOGIES INC | $952,000 | -35.7% | 2,906,037 | 0.0% | 0.19% | -50.4% | |
| ITEK | INOTEK PHARMACEUTICALS CORP | $804,000 | -67.2% | 401,764 | 0.0% | 0.16% | -74.7% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $513,000 | +13.2% | 125,000 | 0.0% | 0.10% | -13.0% | |
| MHK | MOHAWK INDS INC | $252,000 | +14.5% | 1,100 | 0.0% | 0.05% | -12.5% | |
| LOW | LOWES COS INC | $214,000 | +15.7% | 2,600 | 0.0% | 0.04% | -10.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.